Aerovate Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AVTE research report →
About the company
Aerovate Therapeutics, Inc. is a clinical-stage biopharmaceutical enterprise focused on innovating therapies to enhance the well-being of patients afflicted with rare cardiopulmonary illnesses across the United States. The company's principal effort involves advancing AV-101, an inhaled dry powder variant of imatinib, which is currently undergoing a Phase 2b/Phase 3 clinical study for the management of pulmonary arterial hypertension.
- CEO
- Timothy P. Noyes
- IPO
- 2021
- Employees
- 4
- HQ
- Waltham, MA, US
Price Chart
- Market Cap
- $77.68M
- P/E
- -7.37
- P/S
- 0.00
- P/B
- 4.19
- EV/EBITDA
- -5.00
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -51.34%
- ROIC
- -44.96%
- Revenue
- $0 · 0.00%
- Net Income
- $-127,410,000 · -82.99%
- EPS
- $-3193.30 · -130772.95%
- Op Income
- $-113,542,000
- FCF YoY
- -33.27%
- 52W High
- $884.98
- 52W Low
- $2.63
- 50D MA
- $88.74
- 200D MA
- $82.18
- Beta
- 0.95
- Avg Volume
- 7.99K
Get TickerSpark's AI analysis on AVTE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 1, 24 | Dake Benjamin T | other | 1,507 |
| Jul 31, 24 | Dake Benjamin T | other | 11,454 |
| Jul 31, 24 | Dake Benjamin T | other | 10,548 |
| Aug 1, 24 | Dake Benjamin T | other | 1,507 |
| Jun 17, 24 | RA CAPITAL MANAGEMENT, L.P. | buy | 928,110 |
| Jun 14, 24 | Eldridge George A | other | 15,000 |
| Jun 14, 24 | Eldridge George A | other | 15,000 |
| Jun 14, 24 | Eldridge George A | sell | 15,000 |
| Jun 14, 24 | Verwijs Marinus | other | 10,600 |
| Jun 14, 24 | Verwijs Marinus | other | 10,600 |
Our AVTE coverage
Recent articles, reports, and earnings notes.
No research on AVTE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AVTE report →Similar companies
Peers in the same neighborhood.